title: A moderate static magnetic field enhances TRAIL-induced apoptosis by the inhibition of Cdc2 and subsequent downregulation of survivin in human breast carcinoma cells.
abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exhibits its potent antitumor activity via membrane receptors on cancer cells without deleterious side effects for normal tissue. However, as many other cancer types, breast cancer cells develop a resistance to TRAIL. In the present study, we reported that exposure to 3.0 mT static magnetic field (SMF) mediated the sensitization of breast cancer cells to TRAIL-induced apoptosis. This effect was significantly reduced by the forced expression of survivin, suggesting the sensitization was mediated at least in part through the inhibition of survivin expression. In addition, SMF alone or in combination with TRAIL induced a cell cycle arrest within the G2 /M phase, and the reduction in the survivin protein level was associated with the downregulated expression of Cdc2, a cyclin B-dependent kinase that is necessary for the entry into the M phase. Taken together, our results demonstrated that SMF promoted TRAIL-induced apoptosis by inhibiting the expression of Cdc2 and, subsequently, survivin. Of note, SMF did not sensitize untransformed human mammary epithelial cells to TRAIL-mediated apoptosis. Therefore, the combined treatment of SMF and TRAIL may offer an attractive strategy for safely treating resistant breast cancers.
authors.affiliation: College of Instrumentation and Electrical Engineering, Jilin University, Changchun, People's Republic of China.
authors.forename: Tingting
authors.initials: T
authors.lastname: Lin
authors.forename: Ling
authors.initials: L
authors.lastname: Wan
authors.forename: Xin
authors.initials: X
authors.lastname: Qi
authors.forename: Wenlong
authors.initials: W
authors.lastname: Shi
authors.forename: Jun
authors.initials: J
authors.lastname: Lin
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D016203:CDC2 Protein Kinase / Q000037:antagonists & inhibitors*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D019926:Cyclin B / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D055909:Magnetic Field Therapy; D060526:Magnetic Fields; D000077022:Survivin; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology*
chemical_list: C107489:BIRC5 protein, human; D019926:Cyclin B; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; D053221:TNF-Related Apoptosis-Inducing Ligand; D016203:CDC2 Protein Kinase
keywords: Cdc2; TRAIL; static magnetic field; survivin